Citi added a “30-day upside catalyst watch” on shares of Dummit Therapeutics while keeping a Buy rating on the name with a $35 price target The firm sees the stock moving higher on HARMONi-6 presentation scheduled for October 19.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics initiated with an Underweight at Barclays
- Summit Therapeutics’ Ivonescimab Shows Promising Trial Results, Offering a Risk-Mitigation Opportunity with a Buy Rating
- Biotech Alert: Searches spiking for these stocks today
- Summit Therapeutics falls -24.1%
- EchoStar sells spectrum licenses to SpaceX, StubHub to launch IPO: Morning Buzz